MYD88 L265P Mutation Detection by PCR, Quantitative
2009318
Ordering Recommendation

Useful in distinguishing lymphoplasmacytic lymphoma (LPL) from other low-grade B-cell lymphoproliferative disorders which may be in the differential diagnosis. Use when monitoring patients with LPL diagnosis and previously identified MYD88 L265P mutation.

Mnemonic
MYD88
Methodology
Real-time Polymerase Chain Reaction
Performed
DNA isolation: Sun-Sat
Testing: Varies
Reported
7-10 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) OR bone marrow (EDTA) OR tissue. 
Specimen Preparation
Whole Blood: Transport 5 mL (Min: 1 mL)
Bone marrow: Transport 3 mL (Min: 1 mL)
FFPE tumor tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. 
Storage/Transport Temperature
Whole blood OR Bone marrow: Refrigerated.
FFPE tumor tissue: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. 
Unacceptable Conditions
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Clotted or severely hemolyzed specimens.
FFPE tumor tissue: Specimens fixed/processed in alternative fixatives or heavy metal fixatives (B-4 or B-5) or tissue sections on slides. Decalcified specimens. 
Remarks
 
Stability
Whole blood OR Bone marrow: Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable
FFPE tumor tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report.

Statement B: Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Code(s)
81305
Components
Component Test Code*Component Chart NameLOINC
2009319MYD88 Source
2009320MYD88 L265P Detection, Result
2009321MYD88 L265P Detection, Quant
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please view this test within the Laboratory Test Directory found at www.aruplab.com
Aliases
  • Lymphoplasmacytic lymphoma
  • Waldenstrom macroglobulinemia